Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(15):1102-1103; doi:10.1093/jnci/95.15.1102
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Friedrich, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedrich, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

From Bedside to Bench: Treatment for Rare Blood Disorder Yields Clues to Disease Mechanism

M. J. Friedrich

The first 10% of the full text of this article appears below.

Imatinib mesylate (Gleevec) burst onto the clinical scene to much fanfare in 2001. One of the first targeted therapies to be used successfully against a cancer—chronic myeloid leukemia (CML)—imatinib has since proven effective in treating other diseases, such as gastrointestinal stromal tumors. Now, new research shows that imatinib is also effective against a rare blood disorder called hypereosinophilic syndrome (HES). Not only has the drug shown remarkable results in about 50% of patients with HES in whom it has been used, it has revealed a previously unknown mechanism that is responsible for some cases of HES.

Gary Gilliland, M.D., Ph.D., associate professor of medicine at Brigham and Women’s Hospital, Boston, and colleagues recently published a study that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?